SystImmune Showcases Promising Breast Cancer Treatment Advances

Author: Evelyn Baker Updated: 05-09-2025 07:12 AM

SystImmune Presents Innovative Data on Iza-bren for Breast Cancer

SystImmune, Inc. has recently announced significant updates in the safety and efficacy profiles of izalontamab brengitecan (iza-bren), which is being investigated as a treatment for locally advanced or metastatic breast cancer. This announcement corresponds with an ongoing Phase 1 clinical study evaluating the promising EGFRxHER3 bispecific antibody-drug conjugate (ADC).

Details of the Presentation

At the upcoming European Society for Medical Oncology (ESMO) Breast 2025 Annual Congress, crucial data from this pivotal study will be showcased. SystImmune is collaborating with Bristol Myers Squibb in the development of iza-bren, reflecting a strong partnership aimed at enhancing cancer treatment options.

Understanding the Clinical Study

The Phase 1 trial primarily focuses on patients diagnosed with locally advanced or metastatic HER2-negative breast cancer. Initial results, which will be presented at ESMO, indicate a robust therapeutic potential even among HER2-negative patients, highlighting the versatility of iza-bren in targeting various breast cancer profiles.

Expert Insights from the Company

Dr. Jonathan Cheng, Chief Medical Officer of SystImmune, expressed optimism regarding the findings, stating, "These data continue to support our conviction that iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer, including those that are HER2 negative, with a manageable safety profile." This perspective underlines SystImmune's commitment to providing effective treatments for patients with limited options.

Key Presentation Information

Here are the details that attendees can look forward to during the ESMO Congress:

Presentation Title: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC)
Presentation No: 302MO
Session Title: Mini Oral Session 2
Speaker: Yiqun Du from Shanghai, China
Session Date & Time: May 16, 2025, from 8:20 AM to 10:10 AM CEST

About Iza-bren and SystImmune

Iza-bren is at the forefront of targeted cancer therapy, designed to effectively bind to EGFR and HER3 proteins, which are frequently expressed in various epithelial tumors. Its innovative mechanism includes blocking these receptors to hinder cancer cell survival signals and inducing cell death through a specialized therapeutic payload.

SystImmune, a dynamic clinical-stage biopharmaceutical company, is pioneering the fight against cancer with its advanced drug development strategies. The company is focusing on expanding its array of bi-specific and antibody-drug conjugate therapies, which exemplify its dedication to innovative cancer treatment. With ongoing clinical trials and a robust pipeline of therapies, SystImmune aims to make significant strides in cancer care.

Frequently Asked Questions

What is izalontamab brengitecan (iza-bren)?

Iza-bren is a bispecific antibody-drug conjugate targeting EGFR and HER3, designed to treat various forms of cancer, including breast cancer.

When will SystImmune present its findings on iza-bren?

SystImmune will present its findings during the ESMO Breast 2025 Annual Congress on May 16, 2025.

How does iza-bren work?

Iza-bren targets specific cancer cell growth factors and blocks their signals, reducing proliferation and activating cell death pathways.

What types of cancer is iza-bren being developed to treat?

This novel therapy aims to address locally advanced or metastatic HER2-negative breast cancer as well as other epithelial tumors.

Who is leading the clinical development of iza-bren?

SystImmune is developing iza-bren in collaboration with Bristol Myers Squibb, focusing on broadening treatment avenues for breast cancer patients.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.